MediWound Ltd. (MDWD) Issues Earnings Results, Hits Estimates
MediWound Ltd. (NASDAQ:MDWD) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.26). The business earned $0.52 million during the quarter, compared to analysts’ expectations of $0.61 million. MediWound had a negative net margin of 2,332.07% and a negative return on equity of 103.14%. The firm’s quarterly revenue was up 420.0% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.17) EPS.
MediWound (NASDAQ:MDWD) opened at 5.80 on Monday. MediWound has a 12-month low of $5.25 and a 12-month high of $10.47. The firm’s 50-day moving average is $6.83 and its 200 day moving average is $7.50. The firm’s market cap is $126.73 million.
A number of equities analysts recently issued reports on the stock. Jefferies Group lowered their price objective on shares of MediWound from $15.00 to $13.00 and set a “buy” rating for the company in a research report on Friday, July 29th. Zacks Investment Research lowered shares of MediWound from a “hold” rating to a “sell” rating in a research note on Wednesday, October 5th. Finally, Wells Fargo & Co. initiated coverage on shares of MediWound in a research note on Wednesday, August 17th. They set an “outperform” rating and a $14.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $13.63.
An institutional investor recently raised its position in MediWound stock. United Services Automobile Association increased its stake in shares of MediWound Ltd. (NASDAQ:MDWD) by 125.9% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 123,440 shares of the biopharmaceutical company’s stock after buying an additional 68,800 shares during the period. United Services Automobile Association owned about 0.56% of MediWound worth $968,000 as of its most recent SEC filing. Institutional investors own 26.67% of the company’s stock.
MediWound Company Profile
MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing and commercializing products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s biopharmaceutical product, NexoBrid, received marketing authorization from the European Union agency (EMA) and the Israeli and Argentinean ministries of health for removal of dead or damaged tissue, known as eschar, in adults with deep partial and full thickness thermal burns, also referred to as severe burns.
Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.